Class
This class exists because two molecules are sold on the same promise — slower aging, longer healthspan — and almost nothing else about them matches. One has one of the smallest human records in this index; the other has the largest randomized literature of any unapproved substance here. Their regulatory positions are nearly identical.
That pairing is the argument the class makes. If a large trial count produced a lawful route, these two would not be filed together; the count is not what decides, and the class is the shortest proof of it available on this site.
Molecules in this class
| Molecule | Class | US status | Position |
|---|---|---|---|
| EpitalonEpithalon; AEDG tetrapeptide | Longevity peptides | PCAC-recommended · pending | Removed from Category 2 in April 2026; PCAC recommended 503A listing in July 2026 on a reported tally; no FDA final rule. Verified August 2026. |
| L-carnosineCarnosine; beta-alanyl-L-histidine | Longevity peptides | No lawful route | Category 3 of the 503A bulks list — nominated without adequate support — despite a large randomized literature, almost all of it oral supplementation. |
Epithalon; AEDG tetrapeptide
Removed from Category 2 in April 2026; PCAC recommended 503A listing in July 2026 on a reported tally; no FDA final rule. Verified August 2026.
Carnosine; beta-alanyl-L-histidine
Category 3 of the 503A bulks list — nominated without adequate support — despite a large randomized literature, almost all of it oral supplementation.
The records are at epitalon, recommended by the advisory committee in July 2026 and awaiting rulemaking, and L-carnosine, nominated without adequate support and sold lawfully as a dietary supplement instead. The human trial record prints the two counts side by side.
The advisory committee voted on one member in July 2026, as reported in secondary accounts (FDA has published no vote record): Epitalon 7–4 with 1 abstaining.
The 2026 WADA Prohibited List names no member of this class. It does not name Epitalon and L-carnosine, and that is not the same as permitted: the relevant sections are expressly non-exhaustive, and section S0 covers any substance with no current approval for human therapeutic use.
The vote ledger and the WADA table carry the sources.
Evidence reviews
Reference tables
Definitions